Uses of 7,8-dihydroxyflavone in preparation of drugs for treatment of optic nerve injury

A technology for optic nerve injury and quercetin, which can be used in drug combinations, nervous system diseases, pharmaceutical formulations, etc., can solve problems such as unsatisfactory clinical efficacy, and achieve good clinical application prospects, treatment of optic nerve injury, and prevention of decline and death.

Inactive Publication Date: 2015-05-20
GUANGZHOU KANGRUI BIOLOGICAL PHARMA TECH CO LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite intensive research efforts in the treatment of optic atrophy, the actual clinical efficacy is unsatisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of 7,8-dihydroxyflavone in preparation of drugs for treatment of optic nerve injury
  • Uses of 7,8-dihydroxyflavone in preparation of drugs for treatment of optic nerve injury
  • Uses of 7,8-dihydroxyflavone in preparation of drugs for treatment of optic nerve injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 17

[0026] Example 17, Protective effect of 8-dihydroxyflavone on retinal ganglion cells (RGC) after excitatory injury of rat retina induced by N-methyl-D-aspartic acid (NDMA)

[0027] 1. Experimental method

[0028] 1.1 Grouping of experimental animals

[0029] Twelve healthy Sprague-Dawley rats, half male and half male, weighing 200-240g. After examination, the cornea was transparent, the iris blood vessels were clear, the pupils were equal in size and round, and they were sensitive to light reflection. The left eye is the model group, and the right eye is the experimental group:

[0030] Model group: NMDA was injected into the vitreous cavity of the left eye;

[0031] Experimental group: NMDA+7,8-dihydroxyflavone was injected into the vitreous cavity of the right eye.

[0032] 1.2 Drug Injection

[0033] Rats were anesthetized by intraperitoneal injection of 3% pentobarbital sodium at 3ml / Kg body weight, compound tropicamide eye drops were used to dilate both eyes, and 0.3...

Embodiment 2

[0053] Example 2 Optic Nerve Trauma Model Therapeutic Effect

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses uses of 7,8-dihydroxyflavone in preparation of drugs for treatment and / or prevention of optic nerve injury. The present invention further discloses a drug having the optic nerve protection effect, and is the preparation prepared by adopting 7,8-dihydroxyflavone as an active ingredient and adding a pharmaceutically-acceptable excipient or an auxiliary component. According to the present invention, the 7,8-dihydroxyflavone provides good protection effects on excitative optic nerve injury and optic nerve mechanical injury, can be used for repairing retinal ganglion cells, and is the new selection for clinical optic nerve injury treatment.

Description

technical field [0001] The invention relates to the use of 7,8-dihydroxyflavone in the preparation of medicines for treating optic nerve damage. Background technique [0002] Optic nerve damage is the visual function damage caused by many eye diseases, which will cause the atrophy of the patient's optic nerve and the irreversible loss of visual function in severe cases. Clinically, there are many diseases that lead to optic atrophy, such as glaucoma, optic nerve contusion, optic canal fracture, genetic disease Leber's disease, metabolic diseases such as diabetes, gangliosidosis, optic neuritis, and optic neuropathy. Although a lot of research work has been carried out on the treatment of optic atrophy, its clinical efficacy is unsatisfactory. [0003] Loss of retinal ganglion cells (RGCs) is a common pathway of optic nerve damage leading to optic atrophy and blindness. At present, it is believed that the possible mechanisms involved include excitatory amino acid toxicity, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P27/02A61P25/02
Inventor 罗红蓉
Owner GUANGZHOU KANGRUI BIOLOGICAL PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap